“…The treatment of Shigella infections involves reducing water and electrolyte disorders and the use of antibiotics such as ampicillin, tetracyclines, erythromycin, azithromycin, sulfamethoxazole-trimethoprim, and quinolones in severe cases (Romero, 1999;León-Ramírez, 2002;Álvarez et al, 2008;Lluque et al, 2015;da Cunha et al, 2017;CDC, 2020). However, an increase in the incidence of antimicrobial resistance has been reported by isolates of Shigella spp., of clinical origin and food, including fish, considering the phenomenon of resistance in food pathogens a global health problem and the development of a Shigella vaccine is taken as a high priority (Guchi and Ashenafi, 2010;Lluque et al, 2015;Hosseini et al, 2016;Ogbonna and Inana, 2018;Noor et al, 2020). The species of the genus Shigella have a phylogenetic relationship with the genera Salmonella and Escherichia, but unlike these, it does not have animal reservoirs, being detected only in humans and in some cases primates that can be considered accidental hosts, meaning that there is a risk of zoonotic transmission, in addition to its presence in the environment being related to faecal contamination (Huss, 1997;Acha and Szyfres, 2001;Lampel, 2009;Elika, 2013;da Cunha et al, 2017).…”